<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01126008</url>
  </required_header>
  <id_info>
    <org_study_id>2009-10-007</org_study_id>
    <nct_id>NCT01126008</nct_id>
  </id_info>
  <brief_title>Concomitant Chemoradiotherapy (CCRT) With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer</brief_title>
  <official_title>A Phase II Trial of Concurrent Chemoradiotherapy With Weekly Docetaxel and Cisplatin for Locally Advanced Head and Neck Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <brief_summary>
    <textblock>
      This phase II trial is evaluating the efficacy of concurrent chemoradiation therapy with&#xD;
      weekly docetaxel and cisplatin combination regimen.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Many studies have shown the superiority of concurrent chemoradiotherapy over radiotherapy&#xD;
      only in locally advanced head and neck cancer. Concurrent chemoradiotherapy with high dose&#xD;
      cisplatin has been universally used regimen. In a large-scaled phase II trial, however,&#xD;
      conducted by the European Organization for the Research and Treatment of Cancer (EORTC),&#xD;
      docetaxel (100mg/m2) plus cisplatin (75mg/ m2) every three weeks regimen produced improved&#xD;
      survival, nonetheless there was significant limitation to deliver full doses of treatment due&#xD;
      to significant hematologic and non-hematologic toxicities. Previously, we showed the safety&#xD;
      of the combination regimen of weekly docetaxel and cisplatin in concurrent chemoradiation&#xD;
      treatment in a phase I study. We determined the MTD of docetaxel to be 20mg/m2 weekly when&#xD;
      concurrently administered with conventional fractionation RT and weekly 20mg/m2 of cisplatin.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2009</start_date>
  <completion_date type="Actual">April 15, 2016</completion_date>
  <primary_completion_date type="Actual">April 15, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete response rate</measure>
    <time_frame>3-4 weeks after completion of CCRT</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>Pretreatment &amp; 3-4 weeks after completion of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival rate</measure>
    <time_frame>2 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>weekly docetaxel and cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CCRT with weekly docetaxel &amp; cisplatin</intervention_name>
    <description>radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks</description>
    <arm_group_label>weekly docetaxel and cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically confirmed squamous cell carcinoma of the head and neck (SCCHN) of one&#xD;
             of following sites : oral cavity, oropharynx, larynx, or hypopharynx&#xD;
&#xD;
          2. Unresectable Stage III - ⅣB disease&#xD;
&#xD;
          3. previously untreated for head &amp; Neck cancer with chemotherapy or radiotherapy&#xD;
&#xD;
          4. 18 and over&#xD;
&#xD;
          5. Performance status ECOG 0-1&#xD;
&#xD;
          6. Absolute neutrophil count ≥ 1,500/mm3&#xD;
&#xD;
          7. Platelet count ≥ 75,000/mm3&#xD;
&#xD;
          8. Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
          9. Bilirubin ≤ 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
         10. AST or ALT, and alkaline phosphatase meeting 1 of the following parameters:Alkaline&#xD;
             phosphatase ≤ 1.5 times ULN AND AST or ALT ≤ 5 times ULN Alkaline phosphatase ≤ 2.5&#xD;
             times ULN AND AST or ALT ≤ 1.5 times ULN Alkaline phosphatase ≤ 5 times ULN AND AST or&#xD;
             ALT ≤ ULN&#xD;
&#xD;
         11. serum creatinine ≤ 1.5 mg/dl or creatinine clearance ≥ 60 ml/min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Distant metastatic disease (M1)&#xD;
&#xD;
          2. Prior chemotherapy or RT for Head and neck cancer&#xD;
&#xD;
          3. Synchronous or concurrent head and neck primary tumors&#xD;
&#xD;
          4. Lip, nasopharynx, nasal cavity, salivary gland, or sinuses&#xD;
&#xD;
          5. No other invasive malignancy within the past 3 years except nonmelanoma skin cancer or&#xD;
             papillary thyroid cancer&#xD;
&#xD;
          6. Other concurrent illness that would preclude study participation&#xD;
&#xD;
          7. Other concurrent physical condition (e.g., infectious disease) that would preclude&#xD;
             study participation&#xD;
&#xD;
          8. pregnant or nursing&#xD;
&#xD;
          9. Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>May 17, 2010</study_first_submitted>
  <study_first_submitted_qc>May 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2010</study_first_posted>
  <last_update_submitted>March 18, 2021</last_update_submitted>
  <last_update_submitted_qc>March 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Keunchil Park</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>locally advanced Squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

